FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US2940972A
(en)
|
1957-06-27 |
1960-06-14 |
Thomae Gmbh Dr K |
Tri-and tetra-substituted pteridine derivatives
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
GB9125001D0
(en)
|
1991-11-25 |
1992-01-22 |
Ici Plc |
Heterocyclic compounds
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO1994026723A2
(en)
|
1993-05-14 |
1994-11-24 |
Genentech, Inc. |
ras FARNESYL TRANSFERASE INHIBITORS
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL115256A0
(en)
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
CA2262403C
(en)
|
1995-07-31 |
2011-09-20 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
KR100466955B1
(ko)
|
1996-02-26 |
2005-06-10 |
에자이 가부시키가이샤 |
항종양제함유조성물
|
TW472045B
(en)
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
ATE286886T1
(de)
|
1997-05-28 |
2005-01-15 |
Aventis Pharma Inc |
Chinolin- und chinoxalin-verbindungen die den von blutplättchen abstammmenden wachstumsfaktor und/oder pdgf- und p56lck-tyrosin-kinase hemmen
|
US6235740B1
(en)
|
1997-08-25 |
2001-05-22 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
WO1999042461A1
(en)
|
1998-02-23 |
1999-08-26 |
Warner-Lambert Company |
Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
|
EP1147094A1
(en)
|
1999-01-15 |
2001-10-24 |
Novo Nordisk A/S |
Non-peptide glp-1 agonists
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
WO2000068424A2
(en)
|
1999-05-05 |
2000-11-16 |
Institut Curie |
Means for detecting and treating pathologies linked to fgfr3
|
MXPA02001108A
(es)
|
1999-09-15 |
2002-08-20 |
Warner Lambert Co |
Pieridinonas como inhibidores de la cinasa.
|
DE10013318A1
(de)
|
2000-03-17 |
2001-09-20 |
Merck Patent Gmbh |
Formulierung enthaltend Chinoxalinderivate
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
US20030235628A1
(en)
|
2001-09-19 |
2003-12-25 |
Rajneesh Taneja |
Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
|
DE60223720T2
(de)
|
2001-12-18 |
2008-10-30 |
Merck & Co., Inc. |
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
|
CN101973998A
(zh)
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
CN100491372C
(zh)
|
2001-12-24 |
2009-05-27 |
阿斯特拉曾尼卡有限公司 |
作为欧若拉激酶抑制剂的取代喹唑啉衍生物
|
JP2003213463A
(ja)
|
2002-01-17 |
2003-07-30 |
Sumitomo Chem Co Ltd |
金属腐食防止剤および洗浄液
|
JP4394960B2
(ja)
|
2002-04-08 |
2010-01-06 |
メルク エンド カムパニー インコーポレーテッド |
Akt活性阻害薬
|
US7074534B2
(en)
|
2002-07-10 |
2006-07-11 |
E. I. Du Pont De Nemours And Company |
Polymeric charge transport compositions and electronic devices made with such compositions
|
US7196090B2
(en)
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
KR20050056227A
(ko)
|
2002-10-03 |
2005-06-14 |
탈자진 인코포레이티드 |
혈관항상성 유지제 및 그의 사용 방법
|
CA2502825A1
(en)
|
2002-10-22 |
2004-05-06 |
Dainippon Pharmaceutical Co., Ltd. |
Stabilized composition
|
AR043059A1
(es)
|
2002-11-12 |
2005-07-13 |
Bayer Pharmaceuticals Corp |
Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
|
US7098332B2
(en)
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
DE602004021558D1
(de)
|
2003-01-17 |
2009-07-30 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
US20040204450A1
(en)
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
EP1620413A2
(en)
|
2003-04-30 |
2006-02-01 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
CA2525547C
(en)
|
2003-05-14 |
2012-07-03 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
MXPA05012645A
(es)
|
2003-05-23 |
2006-02-08 |
Zentaris Gmbh |
Piridopirazinas novedosas y su uso como moduladores de cinasa.
|
DE10323345A1
(de)
|
2003-05-23 |
2004-12-16 |
Zentaris Gmbh |
Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
|
WO2005007099A2
(en)
|
2003-07-10 |
2005-01-27 |
Imclone Systems Incorporated |
Pkb inhibitors as anti-tumor agents
|
CA2533417A1
(en)
|
2003-07-21 |
2005-02-03 |
Mitchell A. Avery |
Design and synthesis of optimized ligands for ppar
|
JP2007501189A
(ja)
|
2003-08-01 |
2007-01-25 |
ジェネラブス テクノロジーズ,インコーポレイテッド |
フラビウイルス科に対する二環式イミダゾール誘導体
|
PT1673092E
(pt)
|
2003-10-17 |
2007-11-23 |
4 Aza Ip Nv |
''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
|
WO2005041940A1
(en)
|
2003-10-30 |
2005-05-12 |
Lupin Ltd. |
Stable formulations of ace inhibitors and methods for preparation thereof
|
JP4890255B2
(ja)
|
2003-11-07 |
2012-03-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
|
KR101118582B1
(ko)
|
2003-11-20 |
2012-02-27 |
얀센 파마슈티카 엔.브이. |
폴리(adp-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
|
BRPI0416853A
(pt)
|
2003-11-24 |
2007-02-13 |
Hoffmann La Roche |
pirazolila e imidazolila pirimidinas
|
KR101164258B1
(ko)
|
2003-12-23 |
2012-07-11 |
아스텍스 테라퓨틱스 리미티드 |
단백질 키나아제 조절제로서의 피라졸 유도체
|
US7098222B2
(en)
|
2004-05-12 |
2006-08-29 |
Abbott Laboratories |
Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
|
US7205316B2
(en)
|
2004-05-12 |
2007-04-17 |
Abbott Laboratories |
Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
|
US7446196B2
(en)
|
2004-06-03 |
2008-11-04 |
Kosan Biosciences, Incorporated |
Leptomycin compounds
|
CN101048388A
(zh)
|
2004-08-31 |
2007-10-03 |
阿斯利康(瑞典)有限公司 |
喹唑啉酮衍生物及其作为B-Raf抑制剂的用途
|
BRPI0516488A
(pt)
|
2004-10-14 |
2008-09-09 |
Hoffmann La Roche |
azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1
|
WO2006040568A1
(en)
|
2004-10-15 |
2006-04-20 |
Astrazeneca Ab |
Quinoxalines as b raf inhibitors
|
EP1659175A1
(en)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Alterations in seborrheic keratoses and their applications
|
CN101132781A
(zh)
|
2004-12-09 |
2008-02-27 |
茵西斯医疗公司 |
在室温下稳定的屈***酚剂型
|
EP1830869B1
(en)
|
2004-12-24 |
2013-05-22 |
Spinifex Pharmaceuticals Pty Ltd |
Method of treatment or prophylaxis
|
MX2007008141A
(es)
|
2005-01-03 |
2007-12-10 |
Lupin Ltd |
Composicion farmaceutica de sustancias labiles en medio acido.
|
EP1848704A4
(en)
|
2005-02-14 |
2011-05-11 |
Bionomics Ltd |
NEW TUBULIN POLYMERIZATION INHIBITORS
|
EP1853261B1
(de)
|
2005-03-03 |
2017-01-11 |
Universität des Saarlandes |
Selektive hemmstoffe humaner corticoidsynthasen
|
EP1881986A2
(en)
|
2005-05-12 |
2008-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
ATE542527T1
(de)
|
2005-05-13 |
2012-02-15 |
Topotarget Uk Ltd |
Pharmazeutische formulierungen von hdac-hemmern
|
AU2006247315A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
GB0513692D0
(en)
|
2005-07-04 |
2005-08-10 |
Karobio Ab |
Novel pharmaceutical compositions
|
CN101296909B
(zh)
|
2005-08-26 |
2011-10-12 |
默克雪兰诺有限公司 |
吡嗪衍生物及其作为pi3k抑制剂的应用
|
JP5270353B2
(ja)
|
2005-10-07 |
2013-08-21 |
エクセリクシス, インク. |
ホスファチジルイノシトール3−キナーゼインヒビターとその使用方法
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
WO2007054556A1
(de)
|
2005-11-11 |
2007-05-18 |
Æterna Zentaris Gmbh |
Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
|
CN1966500B
(zh)
|
2005-11-17 |
2011-03-30 |
中国科学院上海药物研究所 |
一类喹喔啉类衍生物、制法及用途
|
US20090247576A1
(en)
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
CN101374843B
(zh)
*
|
2005-12-21 |
2012-09-05 |
詹森药业有限公司 |
作为酪氨酸激酶调节剂的***并哒嗪
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
WO2007125405A2
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
GB0609621D0
(en)
|
2006-05-16 |
2006-06-21 |
Astrazeneca Ab |
Novel co-crystal
|
US20100234347A1
(en)
|
2006-05-24 |
2010-09-16 |
Boehringer Ingelheim Internationl Gmbh |
Substituted Pteridines substituted with a Four-Membered Heterocycle
|
JO3235B1
(ar)
|
2006-05-26 |
2018-03-08 |
Astex Therapeutics Ltd |
مركبات بيررولوبيريميدين و استعمالاتها
|
EP2044027A2
(en)
|
2006-07-03 |
2009-04-08 |
Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg |
Fused bicyclic compounds interacting with the histamine h4 receptor
|
EP2056829B9
(en)
|
2006-08-16 |
2012-09-26 |
Exelixis, Inc. |
Using pi3k and mek modulators in treatments of cancer
|
EP2081928B1
(en)
|
2006-11-10 |
2014-02-26 |
Bristol-Myers Squibb Company |
Pyrrolo-pyridine kinase inhibitors
|
JP2008127446A
(ja)
|
2006-11-20 |
2008-06-05 |
Canon Inc |
1,5−ナフチリジン化合物及び有機発光素子
|
CN103288833B
(zh)
|
2006-11-22 |
2018-01-12 |
因塞特控股公司 |
作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
|
EP2104501B1
(en)
|
2006-12-13 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with igf1r inhibitors
|
WO2008080015A2
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2008078091A1
(en)
|
2006-12-22 |
2008-07-03 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
BRPI0720563A2
(pt)
|
2006-12-22 |
2014-02-04 |
Novartis Ag |
Quinazolinas para inibição de pdk1
|
KR20080062876A
(ko)
|
2006-12-29 |
2008-07-03 |
주식회사 대웅제약 |
신규한 항진균성 트리아졸 유도체
|
WO2008109369A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
|
US8163923B2
(en)
|
2007-03-14 |
2012-04-24 |
Advenchen Laboratories, Llc |
Spiro substituted compounds as angiogenesis inhibitors
|
EP1990342A1
(en)
|
2007-05-10 |
2008-11-12 |
AEterna Zentaris GmbH |
Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
|
PE20090288A1
(es)
|
2007-05-10 |
2009-04-03 |
Smithkline Beecham Corp |
Derivados de quinoxalina como inhibidores de la pi3 quinasa
|
JP2010529031A
(ja)
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Pi3キナーゼ阻害剤としてのナフチリジン誘導体
|
AR066879A1
(es)
|
2007-06-08 |
2009-09-16 |
Novartis Ag |
Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
|
BRPI0813105A2
(pt)
|
2007-06-20 |
2015-08-04 |
Mitsubishi Tanabe Pharma Corp |
Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
|
EP2170894A1
(en)
|
2007-06-21 |
2010-04-07 |
Janssen Pharmaceutica N.V. |
Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
|
WO2009009016A1
(en)
|
2007-07-06 |
2009-01-15 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US7981903B2
(en)
|
2007-08-08 |
2011-07-19 |
Glaxosmithkline Llc |
2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
|
WO2009021083A1
(en)
|
2007-08-09 |
2009-02-12 |
Smithkline Beecham Corporation |
Quinoxaline derivatives as pi3 kinase inhibitors
|
WO2009019518A1
(en)
|
2007-08-09 |
2009-02-12 |
Astrazeneca Ab |
Pyrimidine compounds having a fgfr inhibitory effect
|
WO2013173485A1
(en)
|
2012-05-15 |
2013-11-21 |
Predictive Biosciences, Inc. |
Detection of bladder cancers
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
EP2220068B1
(en)
|
2007-11-16 |
2016-01-27 |
Incyte Holdings Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
UA101487C2
(en)
|
2007-12-21 |
2013-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Humanized b-ly1 antibody formulation
|
EP2282739A2
(en)
|
2008-05-05 |
2011-02-16 |
Schering Corporation |
Sequential administration of chemotherapeutic agents for treatment of cancer
|
UA103478C2
(ru)
|
2008-05-23 |
2013-10-25 |
Новартіс Аг |
Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы
|
CN103705942B
(zh)
|
2008-11-15 |
2016-08-24 |
麦林塔医疗有限公司 |
抗微生物组合物
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
CA2750047A1
(en)
|
2009-01-21 |
2010-07-29 |
Basilea Pharmaceutica Ag |
Novel bicyclic antibiotics
|
EP2391623A4
(en)
|
2009-02-02 |
2012-09-05 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
TW201041888A
(en)
|
2009-05-06 |
2010-12-01 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
BRPI1012892B8
(pt)
|
2009-06-12 |
2021-05-25 |
Abivax |
compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
MX2012002274A
(es)
|
2009-09-03 |
2012-09-07 |
Bioenergenix |
Compuestos heterociclicos para la inhibicion de pask.
|
CN102596932A
(zh)
|
2009-09-04 |
2012-07-18 |
拜耳医药股份有限公司 |
作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
|
AU2010297357B2
(en)
|
2009-09-18 |
2013-11-07 |
Sanofi-Aventis Deutschland Gmbh |
(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
|
US20110123545A1
(en)
|
2009-11-24 |
2011-05-26 |
Bristol-Myers Squibb Company |
Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
|
EP2332939A1
(en)
|
2009-11-26 |
2011-06-15 |
Æterna Zentaris GmbH |
Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
|
KR20130053404A
(ko)
|
2010-03-30 |
2013-05-23 |
베르선 코포레이션 |
트롬빈 억제제로서의 다중치환된 방향족 화합물
|
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
US8513421B2
(en)
|
2010-05-19 |
2013-08-20 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
WO2011149937A1
(en)
|
2010-05-24 |
2011-12-01 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CN102532141A
(zh)
*
|
2010-12-08 |
2012-07-04 |
中国科学院上海药物研究所 |
[1,2,4]***并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
|
AP2013007043A0
(en)
|
2011-01-31 |
2013-08-31 |
Novartis Ag |
Novel heterocyclic derivatives
|
WO2012106556A2
(en)
|
2011-02-02 |
2012-08-09 |
Amgen Inc. |
Methods and compositons relating to inhibition of igf-1r
|
JP6130305B2
(ja)
|
2011-02-23 |
2017-05-17 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせおよびそれらの使用
|
WO2012118492A1
(en)
|
2011-03-01 |
2012-09-07 |
Array Biopharma Inc. |
Heterocyclic sulfonamides as raf inhibitors
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2747767B8
(en)
|
2011-08-26 |
2019-07-17 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013089882A2
(en)
|
2011-09-27 |
2013-06-20 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in breast cancer
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
JP6059731B2
(ja)
|
2011-10-28 |
2017-01-11 |
ノバルティス アーゲー |
新規プリン誘導体および疾患の処置におけるその使用
|
GB201118656D0
(en)
*
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
WO2013088191A1
(en)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
|
AU2013228389A1
(en)
|
2012-03-08 |
2014-09-25 |
Astellas Pharma Inc. |
Novel FGFR3 fusion product
|
EP2833917A1
(en)
|
2012-04-03 |
2015-02-11 |
Novartis AG |
Tyrosine kinase inhibitor combinations and their use
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
WO2014007369A1
(ja)
|
2012-07-05 |
2014-01-09 |
独立行政法人国立がん研究センター |
Fgfr2融合遺伝子
|
EP2869816A4
(en)
|
2012-07-09 |
2016-04-20 |
Coherus Biosciences Inc |
FORMANTS OF ETANERCEPT HAVING A REDUCTION MARKED IN INVISIBLE PARTICLES IN THE NU
|
EP4276200A3
(en)
|
2012-07-24 |
2024-02-14 |
The Trustees of Columbia University in the City of New York |
Fgfr-tacc fusion proteins and methods thereof
|
US20150203589A1
(en)
|
2012-07-24 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Fusion proteins and methods thereof
|
US20140030259A1
(en)
|
2012-07-27 |
2014-01-30 |
Genentech, Inc. |
Methods of treating fgfr3 related conditions
|
AU2013320972B2
(en)
|
2012-09-27 |
2018-08-30 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR3 fusion gene and pharmaceutical drug targeting same
|
WO2014071419A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
EA201590788A1
(ru)
|
2012-11-07 |
2015-12-30 |
Тева Фармасьютикал Индастриз Лтд. |
Аминные соли лахинимода
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014165710A2
(en)
|
2013-04-05 |
2014-10-09 |
Life Technologies Corporation |
Gene fusions
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
EP3004380A2
(en)
|
2013-05-27 |
2016-04-13 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Novel translocations in lung cancer
|
US20160129030A1
(en)
|
2013-06-14 |
2016-05-12 |
The Brigham And Women's Hospital, Inc. |
Treatment of mtor hyperactive related diseases and disorders
|
WO2014198337A1
(en)
|
2013-06-14 |
2014-12-18 |
Synthon B.V. |
Stable and water soluble pharmaceutical compositions comprising pemetrexed
|
WO2015006723A1
(en)
|
2013-07-12 |
2015-01-15 |
The Regents Of The University Of Michigan |
Recurrent gene fusions in cancer
|
WO2015017607A2
(en)
*
|
2013-08-02 |
2015-02-05 |
Cephalon, Inc. |
METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
JP6980385B2
(ja)
|
2014-03-26 |
2021-12-15 |
アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited |
Fgfr阻害剤とigf1r阻害剤の組合せ
|
HUE053654T2
(hu)
|
2014-03-26 |
2021-07-28 |
Astex Therapeutics Ltd |
FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
|
JO3512B1
(ar)
|
2014-03-26 |
2020-07-05 |
Astex Therapeutics Ltd |
مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
|
EP4063516A1
(en)
|
2014-09-26 |
2022-09-28 |
Janssen Pharmaceutica NV |
Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
|
JOP20200201A1
(ar)
|
2015-02-10 |
2017-06-16 |
Astex Therapeutics Ltd |
تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
|
CN107635583A
(zh)
|
2015-02-19 |
2018-01-26 |
生物临床医疗公司 |
用于治疗癌症的方法、组合物和试剂盒
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN105030777B
(zh)
|
2015-07-14 |
2017-07-21 |
中国人民解放军第三军医大学第三附属医院 |
增强alk‑tki疗效、延缓其耐药的复合物及其制剂
|
CN105147687A
(zh)
|
2015-09-28 |
2015-12-16 |
青岛华之草医药科技有限公司 |
一种治疗白血病的药物达沙替尼组合物胶囊
|
JOP20190280A1
(ar)
|
2017-06-02 |
2019-12-02 |
Janssen Pharmaceutica Nv |
مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
|